Compare Adaptive Biotechnologies Corp (ADPT) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Marvell Technology Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Marvell Technology Inc trades at $222.48 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 47.2× Adaptive Biotechnologies Corp's market cap, and Marvell Technology Inc pays a 0.11% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MRVL | |
|---|---|---|
Market Cap | $4.04B | $190.56B |
Sector | Health | Technology |
52-Week High | $25.45 | $316.43 |
52-Week Low | $12.30 | $62.31 |
Enterprise Value | $4.10B | $191.99B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Marvell Technology (MRVL) trades at $221.15, up 6.04% today, reflecting strong momentum amid AI-driven optimism. The stock exhibits a bullish technical signal with moving averages supporting the uptrend, while recent earnings beats and a consensus analyst price target of $275.68 highlight fundamental strength. Key developments include partnerships with NVIDIA and Microsoft's Maia 300 AI accelerator, positioning MRVL for growth in data center and networking segments.
Outlook remains positive with AI infrastructure expansion driving revenue projections to $8.7B in 2026, though high valuation ratios (P/E 72.96) and supply chain risks warrant caution. Net income turned profitable in 2026 forecasts, but competitive pressures and market volatility pose challenges. Analyst consensus is strongly bullish with 82% buy ratings, suggesting upside potential if execution aligns with growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
